Voriconazole For Chronic Bronchopulmonary Aspergillosis

Status Completed

Clinical Trial Summary

To evaluate the efficacy of voriconazole (VFend(R)) as first line treatment for proven chronic bronchopulmonary aspergillosis, in minimally immunocompromised or non-immunocompromised patients after 6 months of treatment i.e. chronic necrotizing pulmonary

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00159822
Study type	Interventional
Source	Pfizer
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	July 2005
Completion date	December 2008

View Details

See also
Status	Clinical Trial	Phase
Suspended	`NCT01887457` - Individualisation of Voriconazole Antifungal Therapy Antifungal Therapy	Phase 2
Completed	`NCT00940017` - A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects	Phase 4
Enrolling by invitation	`NCT01617759` - Aspergillus-specific PCR Assay in Cerebrospinal Fluid Samples for Detection of Central Nervous System Aspergillosis
Terminated	`NCT03905447` - The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients.	Phase 2
Recruiting	`NCT04744454` - Post Marketing Surveillance (PMS) Study of Cresemba in Korea.
Completed	`NCT02715570` - A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945	Phase 1
Withdrawn	`NCT01622595` - UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients	N/A
Completed	`NCT00001937` - Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients	Phase 3
Completed	`NCT04935463` - Mucormycosis in COVID-19
Withdrawn	`NCT01188759` - Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects	Phase 3
Completed	`NCT00473252` - Surveillance of Fungal Infections During Construction Activity	N/A
Completed	`NCT00037206` - A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).	Phase 2/Phase 3
Completed	`NCT04818853` - COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI)
Completed	`NCT00412893` - Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis	Phase 3
Recruiting	`NCT06135597` - Immune Regulation in Chronic Aspergillus Infection After COVID-19 Infection
Terminated	`NCT02646800` - Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp	Phase 4
Completed	`NCT00854607` - An Observational Study of Fungal Biomarkers (MK-0000-089)	N/A
Completed	`NCT00388167` - Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection	Phase 4
Completed	`NCT05065658` - Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients
Completed	`NCT00005912` - Voriconazole to Prevent Systemic Fungal Infections in Children	Phase 1